Alvotech and Islandsbanki have renewed their market making agreement to enhance liquidity and trading in ALVO shares.
Quiver AI Summary
Alvotech and Islandsbanki have renewed and revised their market-making agreement, allowing Islandsbanki to facilitate trading of Alvotech shares on the Nasdaq Iceland Main Market. Under the agreement, Islandsbanki will place bids and offers, ensuring at least ISK 8 million in market value for Alvotech shares while maintaining a maximum spread of 2.5%. Additionally, Islandsbanki's daily trading volume will be capped at ISK 16 million. The agreement, which was amended on May 29, 2026, has no fixed duration and can be terminated by either party with a 7-day notice. Alvotech is a biotechnology company specializing in biosimilars, with several products already approved and a pipeline of candidates for various diseases.
Potential Positives
- Renewal and amendment of the market-making agreement with Islandsbanki aims to enhance liquidity and transparent price formation for Alvotech's shares.
- The agreement ensures that Islandsbanki will maintain significant market value for Alvotech's shares, thereby potentially increasing investor interest and trade volume.
- Alvotech's strategy to leverage partnerships and market making may improve its visibility and credibility in the biotechnology sector, supporting its goal to be a global leader in biosimilars.
Potential Negatives
- The lack of a fixed term for the amended market-making agreement may result in uncertainty regarding ongoing support for share liquidity and pricing transparency.
- Islandsbanki's obligation to maintain bid and ask quotes is limited by daily trading volume caps, which could hinder consistent trading activity for Alvotech's shares.
- The possibility for Islandsbanki to terminate the agreement with only 7-days notice raises concerns about the stability of market making for Alvotech's shares.
FAQ
What is the purpose of the amended market making agreement with Islandsbanki?
The agreement aims to increase trading, liquidity, and transparent price formation for Alvotech's shares on Nasdaq Iceland.
What are the bid and ask quote requirements for Islandsbanki?
Islandsbanki must maintain a minimum market value of ISK 8 million in bid and ask quotes for Alvotech's shares.
How often does Islandsbanki refresh bid and ask quotes?
Islandsbanki is required to refresh quotes within 15 minutes after they are executed in full.
What is the maximum spread allowed between bid and ask quotes?
The maximum spread is set at 2.5% based on the average bid and ask quotes for Alvotech's shares.
How can the market making agreement be terminated?
Either party can terminate the agreement with 7 days' prior notice to the other party.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ALVO Hedge Fund Activity
We have seen 36 institutional investors add shares of $ALVO stock to their portfolio, and 37 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MILLENNIUM MANAGEMENT LLC added 1,765,420 shares (+494.3%) to their portfolio in Q1 2026, for an estimated $6,055,390
- POINTSTATE CAPITAL LP removed 1,049,039 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $3,598,203
- OAKTREE CAPITAL MANAGEMENT LP removed 1,030,020 shares (-65.9%) from their portfolio in Q4 2025, for an estimated $5,284,002
- UBS GROUP AG added 186,097 shares (+136.8%) to their portfolio in Q1 2026, for an estimated $638,312
- NORGES BANK removed 180,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $923,400
- VANGUARD GROUP INC added 141,948 shares (+3.3%) to their portfolio in Q4 2025, for an estimated $728,193
- MARSHALL WACE, LLP removed 136,859 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $702,086
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$ALVO Price Targets
Multiple analysts have issued price targets for $ALVO recently. We have seen 2 analysts offer price targets for $ALVO in the last 6 months, with a median target of $5.0.
Here are some recent targets:
- Glen Santangelo from Barclays set a target price of $4.0 on 03/24/2026
- Ashwani Verma from UBS set a target price of $6.0 on 03/24/2026
Full Release
REYKJAVIK, ICELAND (June 1, 2026) — Alvotech (Nasdaq: ALVO) and Islandsbanki have renewed and amended their existing market making agreement. According to the agreement, Islandsbanki places bids and offers for ALVO shares trading on the Nasdaq Iceland Main Market (the “Exchange”) for a minimum amount with a fixed spread between the bid and offer price.
The objective of the market-making agreement is to increase trade in Alvotech’s shares, liquidity and transparent price formation.
As a market maker, Islandsbanki will post bid and ask quotes on the Exchange with an aggregate market value of at least ISK 8 million prior to the start of daily trading. Both the bid and ask quotes shall be refreshed as soon as possible but no later than 15 minutes after being executed in full. Islandsbanki aims to maintain more than one bid and/or ask quote for Alvotech’s shares such that the total market value of outstanding quotes is at least ISK 8 million at all times, but the bank is not obligated to maintain multiple bid or ask quotes. Islandsbanki also reserves the right to post additional bid and ask quotes even if existing quotes remain unexecuted.
The maximum spread between bid and ask quotes is 2.5%, calculated as the volume weighted average of the bid and ask quotes for Alvotech’s shares posted by Islandsbanki as market maker at any given time. The daily net volume of trades by Islandsbanki as a market maker in Alvotech’s shares shall be limited to ISK 16 million. This amount is calculated as the difference between bids and asks by Islandsbanki that have been executed in full. When the maximum amount is reached, Islandsbanki is under no further obligation during that day to post either a bid or ask quote, depending on which side has been filled. Once a quote on the opposite side is executed and the daily net volume falls below the ISK 16 million mark, the market maker’s obligation to post bid and ask quotes is restored.
The amended agreement was executed on May 29, 2026, and has no fixed term. Each party has the right to terminate the agreement by giving a 7-day prior notice.
About Alvotech
Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in biosimilars by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit https://www.alvotech.com . None of the information on the Alvotech website shall be deemed part of this press release.
For more information, please visit our investor portal , and our website or follow us on social media on LinkedIn , Facebook , Instagram and YouTube .
ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONS
Benedikt Stefansson, VP
[email protected]
